MedPath

Transcranial Direct Current Stimulation to Enhance Training Effectiveness in Chronic Post-Stroke Aphasia

Not Applicable
Active, not recruiting
Conditions
Post-stroke
Aphasia
Interventions
Other: Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
Registration Number
NCT03930121
Lead Sponsor
University Medicine Greifswald
Brief Summary

The aim of the study is to investigate whether intensive speech-language therapy (SLT) combined with anodal transcranial direct current stimulation (tDCS) leads to better communication performance than SLT combined with placebo stimulation (using sham-tDCS).

Detailed Description

Intensive speech-language therapy (SLT) can promote recovery from chronic post-stroke aphasia, but effect sizes are moderate. This highlights the pressing need to explore adjunct strategies, such as transcranial direct current stimulation (tDCS), to enhance training effectiveness. Recently, the investigators provided evidence from a single-center randomized controlled trial (RCT) suggesting that anodal-tDCS of the left primary motor cortex (M1) improves naming and communication ability in chronic post-stroke aphasia, with medium-to-large effect sizes. However, prior to integration into clinical routine, a multi-center RCT with adequate power, duration, and outcomes relevant to everyday life is required, which is the goal of the present study. After trial completion, a workshop with relevant stakeholders will ensure transfer into best-practice guidelines.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
130
Inclusion Criteria
  • left-hemisphere cortical or subcortical stroke with first-ever aphasic symptoms
  • at least 6 months post-onset of stroke;
  • aphasia, as determined by the Aachen Aphasia Test (AAT);
  • 13 moderate-to-severe word finding difficulties (maximum of 75% correct items on a computerized naming task at baseline);
  • at least 1 correct reaction on the first part of the AAT subscale Token Test (ensuring basic comprehension skills);
  • at least 1 point on the communicative task of the AAT subscale Spontaneous Speech (ensuring basic communication abilities);
  • German as first language;
  • intact left-hemisphere "hand knob" without right prefrontal lesions for placement of tDCS electrodes, as confirmed by magnetic resonance imaging or computer tomography scans.
Exclusion Criteria
  • contraindications for tDCS (e.g., cardiac pacemaker, history of seizures, implanted metal inside the head);
  • more than one clinically apparent stroke with aphasic symptoms;
  • other severe neurological diseases (e.g., brain tumor, and subdural hematoma);
  • epilepsy with seizures during the last 12 months prior to study start and/or intake of sedating antiepileptic drugs (barbiturates and benzodiazepines),
  • history of severe alcohol or drug abuse;
  • current severe depression;
  • current psychosis or other relevant psychiatric condition;
  • very severe apraxia of speech, as revealed by Hierarchical Word Lists;
  • severe non-verbal cognitive deficits, as indicated by the Corsi Block-Tapping Task;
  • severe uncontrolled medical problems;
  • severely impaired vision or hearing that prevents patients from engaging in intensive SLT;
  • changes in centrally active drugs within 2 weeks prior to study inclusion.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupAnodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)Placebo stimulation (using sham-tDCS) combined with SLT
Experimental groupAnodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
Primary Outcome Measures
NameTimeMethod
Change in communication ability, as assessed by the Amsterdam Nijmegen Everyday Language TestBefore the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Amsterdam Nijmegen Everyday Language Test (A-scale; parallel versions used in counterbalanced order across participants); cf. Blomert L, Kean ML, Koster C, et al. Amsterdam-Nijmegen Everyday Language Test-Construction, Reliability and Validity. Aphasiology 1994; 8: 381-407.

Secondary Outcome Measures
NameTimeMethod
Change in (non-)verbal communication, as assessed by the Scenario TestBefore the 3-week treatment period; 6-month follow-up

Scenario Test; cf. Nobis-Bosch R, Abel S, Krzok F, et al. Szenario Test-Testung verbaler und nonverbaler Aspekte aphasischer Kommunikation. ProLog, in preparation.

Change in attention and executive function, as assessed by the subscales Go/NoGo and Alertness from Test of Attentional PerformanceBefore the 3-week treatment period; 6-month follow up

Subscales Go/NoGo and Alertness from Test of Attentional Performance; cf. Zimmermann P and Fimm B. Testbatterie zur Aufmerksamkeitsprüfung (TAP). Herzogenrath: PSYTEST Verlag, 2002.

Change in health-related quality of life, as assessed by the EuroQol Health-Related Quality of Life QuestionnaireBefore the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

EuroQol Health-Related Quality of Life Questionnaire (EQ-5D-5L); cf. EuroQol G. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.

Change in direct and indirect costs during the 12-month study period, as assessed by the Quality-Adjusted Life YearsBefore the 3-week treatment period; 6- and 12-month follow ups

Quality-Adjusted Life Years; cf. Whitehead SJ and Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010; 96: 5-21.

Change in mood, as assessed by the German version of the 10-item Stroke Aphasic Depression QuestionnaireBefore the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

German version of the 10-item Stroke Aphasic Depression Questionnaire (SADQH-10); cf. Cobley CS, Thomas SA, Lincoln NB, et al. The assessment of low mood in stroke patients with aphasia: reliability and validity of the 10-item Hospital version of the Stroke Aphasic Depression Questionnaire (SADQH-10). Clin Rehabil 2012; 26: 372-381.

Change in direct and indirect costs during the 12-month study period, as assessed by the self-developed Patient Resource Consumption QuestionnaireBefore the 3-week treatment period; 6- and 12-month follow ups

Direct and indirect costs during the 12-month study period, as determined by the self-developed Patient Resource Consumption Questionnaire considering common standardized unit cost assumptions.

Change in unpaid support provided by family members or friends, as assessed by the Burden of informal caregiversBefore the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Burden of informal caregivers; cf. van Exel NJ, Koopmanschap MA, van den Berg B, et al. Burden of informal caregiving for stroke patients. Identification of caregivers at risk of adverse health effects. Cerebrovasc Dis 2005; 19: 11-17.

Change in naming ability, as assessed based on personally relevant trained and untrained items, consistent with previous work (see description)Before the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Personally relevant trained and untrained items, consistent with previous work; cf. Meinzer M, Darkow R, Lindenberg R, et al. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. Brain 2016; 139: 1152-1163.

Change in (non-)verbal communication, as assessed by the Communicative Effectiveness IndexBefore the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Communicative Effectiveness Index; cf. Lomas J, Pickard L, Bester S, et al. The Communicative Effectiveness Index: development and psychometric evaluation of a functional communication measure for adult aphasia. J Speech Hear Disord 1989; 54: 113-124.

Change in non-verbal episodic memory, as assessed by the Figure Recognition Task from Benton Visual Retention TestBefore the 3-week treatment period; 6-month follow up

Figure Recognition Task from Benton Visual Retention Test; cf. Benton Sivan A and Spreen O. Benton Test. Bern: Huber, 2009.

Change in health-related quality of life, as assessed by the Stroke and Aphasia Quality of Life ScaleBefore the 3-week treatment period; immediately after the 3-week treatment period; 6- and 12-month follow ups

Stroke and Aphasia Quality of Life Scale (SAQOL-39g); cf. Hilari K, Lamping DL, Smith SC, et al. Psychometric properties of the Stroke and Aphasia Quality of Life Scale (SAQOL-39) in a generic stroke population. Clin Rehabil 2009; 23: 544-557.

Trial Locations

Locations (19)

EUFH Rostock

🇩🇪

Rostock, Germany

University Medicine Greifswald, Department of Neurology

🇩🇪

Greifswald, Germany

Aphasiestation RWTH Aachen

🇩🇪

Aachen, Germany

Kliniken Schmieder Allensbach

🇩🇪

Allensbach, Germany

Schön Klinik Bad Aibling Harthausen

🇩🇪

Bad Aibling, Germany

Wicker Klinik Bad Homburg

🇩🇪

Bad Homburg, Germany

Moritz Kliniken Bad Klosterlausnitz

🇩🇪

Bad Klosterlausnitz, Germany

Median Klinik Bad Sülze

🇩🇪

Bad Sülze, Germany

ZAR Berlin

🇩🇪

Berlin, Germany

Kliniken Schmieder Gailingen

🇩🇪

Gailingen, Germany

BDH-Klinik Greifswald gGmbH

🇩🇪

Greifswald, Germany

Klinikum Christophsbad Göppingen

🇩🇪

Göppingen, Germany

Kliniken Schmieder Heidelberg

🇩🇪

Heidelberg, Germany

Hospital zum Heiligen Geist Kempen

🇩🇪

Kempen, Germany

Tagesklinik MPI Leipzig

🇩🇪

Leipzig, Germany

Logo Zentrum Lindlar

🇩🇪

Lindlar, Germany

TheraVent aktiv Marbach

🇩🇪

Marbach, Germany

St. Mauritius Therapieklinik

🇩🇪

Meerbusch, Germany

Aphasie-Zentrum Vechta gGmbH

🇩🇪

Vechta, Germany

© Copyright 2025. All Rights Reserved by MedPath